Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Surzetoclax · ABBV-453

Small molecule · developed by AbbVie

Phase 1/2 Most advanced trial
ABBV Developer

What is Surzetoclax?

Surzetoclax (ABBV-453) is a drug studied in multiple myeloma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ABBV-453
Drug type
Small molecule
Therapy area
Oncology
Developer
AbbVie (ABBV)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
C3TU3CHH6L

Conditions studied

Multiple Myeloma

More from AbbVie

Follow ABBV, the company behind Surzetoclax

See ABBV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABBV catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.